User profiles for Carsten Utoft Niemann
 | Carsten NiemannRigshospitalet, Copenhagen University Hospital, Department of Hematology Verified email at regionh.dk Cited by 8610 |
Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy
The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19.
We here demonstrate suppressive but not curative effect of remdesivir in an …
We here demonstrate suppressive but not curative effect of remdesivir in an …
Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell …
…, R Rosenquist, CU Niemann… - Cytometry Part B …, 2018 - Wiley Online Library
The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches
have limitations affecting reproducibility and there is no consensus on the role of new …
have limitations affecting reproducibility and there is no consensus on the role of new …
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
…, H Toldbod, LB Pedersen, CU Niemann… - The Lancet …, 2018 - thelancet.com
Background Regimens based on ibrutinib alone and lenalidomide and rituximab in
combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We …
combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We …
[HTML][HTML] Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors
We report on markedly different frequencies of genetic lesions within subsets of chronic
lymphocytic leukemia patients carrying mutated or unmutated stereotyped B-cell receptor …
lymphocytic leukemia patients carrying mutated or unmutated stereotyped B-cell receptor …
Real‐world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib
…, MA Andersen, CU Niemann - European journal of …, 2020 - Wiley Online Library
Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both
front‐line setting and as later‐line treatment. However, knowledge about the outcomes and …
front‐line setting and as later‐line treatment. However, knowledge about the outcomes and …
The CLL-IPI applied in a population-based cohort
…, I Christiansen, CU Niemann - Blood, The Journal of …, 2016 - ashpublications.org
The rapid development in treatment options for patients with chronic lymphocytic leukemia (CLL)
in parallel with a much more detailed understanding of the underlying pathogenesis …
in parallel with a much more detailed understanding of the underlying pathogenesis …
[HTML][HTML] First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+ Ven) versus chlorambucil plus …
…, N Schuier, K Baeten, DB Caces, CU Niemann… - Blood, 2021 - Elsevier
Background: MRD status is an established predictive marker for progression-free survival (PFS)
in CLL following chemoimmunotherapy as well as for fixed-duration treatment with …
in CLL following chemoimmunotherapy as well as for fixed-duration treatment with …
[HTML][HTML] And predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study
…, C da Cunha-Bang, M Helleberg, CU Niemann - …, 2018 - ncbi.nlm.nih.gov
With the international prognostic index for patients with chronic lymphocytic leukemia (CLL-IPI),
we have a tool to identify patients with a high risk of progression. 1, 2 Despite improved …
we have a tool to identify patients with a high risk of progression. 1, 2 Despite improved …
Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death
Comorbid conditions are highly prevalent in chronic lymphocytic leukemia (CLL), nevertheless,
detailed information on the association of specific comorbidities with CLL prognosis is …
detailed information on the association of specific comorbidities with CLL prognosis is …
Targeting Bruton's tyrosine kinase across B-cell malignancies
C da Cunha-Bang, CU Niemann - Drugs, 2018 - Springer
… Carsten Utoft Niemann has received grants from Janssen and Abbvie; consulting fees
from Roche, Gilead, Janssen, Abbvie, AstraZeneca, and CSL Behring; and travel support to …
from Roche, Gilead, Janssen, Abbvie, AstraZeneca, and CSL Behring; and travel support to …
